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Abstract
Background: Depressed pregnant women face difficulty navigating a course between the potentially serious
consequences of leaving depression untreated and significant limitations associated with conventional therapies,
such as foetal toxicity and teratogenicity. Preliminary evidence is suggestive that acupuncture may provide a safe
and effective alternative treatment option for antenatal depression; however, additional research is required. The
purpose of this study is to further investigate this treatment possibility, with an additional examination of a
potential biomechanistic acupuncture effect.
Methods/design: In this pragmatic randomised controlled trial, we will compare individually tailored, flexible
antenatal depression-oriented acupuncture with equivalent attention progressive muscle relaxation and routine
antenatal depression hospital care. Eligible women at 24 weeks of gestation with Edinburgh Postnatal Depression
Scale scores of 13 or more will be recruited from 2 antenatal clinics in South Western Sydney, Australia. The
recruitment goal of 96 is powered to demonstrate a significant difference in Edinburgh Postnatal Depression
Scale score severity between acupuncture and usual care, with intervention groups receiving weekly 1-h
treatments for 8 weeks from 24 to 31 weeks of gestation. Mental health and quality-of-life assessments will
occur at study commencement, intervention weeks 4 and 8 and 6 weeks post-natally via the collection of
completed Edinburgh Postnatal Depression Scale scores, Depression, Stress and Anxiety Scale scores and World Health
Organisation Quality of Life Scale scores. Adjustment to mothering will also be evaluated at 6 weeks post-natally using
the Being a Mother Scale. A putative biomechanistic effect of acupuncture on the oxytocinergic system will
additionally be examined by comparing baseline salivary hormone levels with those measured at intervention
weeks 4 and 8, as well as leucocyte oxytocin receptor expression at baseline and intervention week 8.
Discussion: Ethical approval was received in February 2015, and recruitment is underway and expected to be
completed in July 2016.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615000250538, Registered on 19
March 2015.
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Background
In developed countries, including Australia, depression
in pregnancy occurs at rates similar to those seen in
non-pregnant women [1, 2], with prevalence reportedly
ranging from 7.4 % [3] to 25 % [4] or higher [1] in
vulnerable at risk groups [1, 4]. Whilst areas of lower
socioeconomic status (SES) have not been identified
as a risk factor in all studies [5], they have been shown to
contribute to the presence of a greater number of individ-
ual psychosocial risks [6] and consequently may result in
increased vulnerability. Morbid consequences include a
significantly increased risk of obstetric complications
[1, 4, 7–11] and post-natal depression in mothers [2, 12],
as well as alterations in growth, development [11, 13],
autonomic neuroendocrine function [4, 14–16] and men-
tal health [4, 14, 17] in offspring. Treatment recommenda-
tions range from psychotherapy or anti-depressants for
moderate cases to electroconvulsive therapy or a tricyclic
combined with an anti-psychotic for depression with
psychosis [18]. Prevailing medical opinion advocates that
the consequences of leaving antenatal depression pharma-
cologically untreated is comparable to or greater than the
risks associated with anti-depressant side effects and tox-
icity [11, 19, 20]. Yet, the efficacy of anti-depressants in
pregnancy remains untested in large randomised con-
trolled trials (RCTs), and, whilst expected to be compar-
able to those observed in non-pregnant populations [21],
pregnancy-related pharmacokinetic changes may necessi-
tate a need for increased dosage [20, 22]. Clinicians often
reduce prescriptions in an attempt to limit foetal expos-
ure, and resultant levels may therefore be subtherapeutic
[22]. Recent evaluations of anti-depressant response rates
in non-pregnant populations report modest improve-
ments ranging from 14 % [23] to 32 % overall [24], and
more than 50 % of cases failing to achieve remission [25].
Treatment compliance is also an issue, with 45 % partially
[26] and 42 % completely discontinuing medication within
the first 3 months [27, 28], due in part to unwanted ad-
verse effects [27, 29]. This is especially the case in
intentionally conceiving or pregnant women, in whom
cessation of medication is particularly common [9, 29],
resulting in relapse rates of 68 % compared to 26 % in
those who continue medication [30]. Combined pharma-
cologic treatments and psychotherapies, although consid-
ered to be more efficacious, also appear to be limited in
regard to depression severity and chronicity [31].
Studies indicate that depressed pregnant women are
reluctant to take anti-depressant medication [9, 32] and
are significantly more likely to voice a preference for
non-pharmacologic options [33, 34]. Preliminary research
into acupuncture for the management of antenatal depres-
sion, although limited to three clinical studies, appears
promising and reflective of similar findings in systematic
reviews of acupuncture as a treatment for depression
[35–37]. In the first antenatal depression RCT, pub-
lished in 2004, Manber and co-workers [38] compared
12 sessions of depression-specific, manualised acupuncture
with ‘sham’ acupuncture and a massage control in 61 preg-
nant women with major depression. Significantly higher
response rates were reported for depression-specific acu-
puncture (69 %) compared with massage (32 %) (p = 0.031)
and a non-significant intermediate response rate in com-
parison to sham (47 %). The depression-specific acupunc-
ture group also demonstrated a significantly higher average
rate of reduction in depression scores within the first
month of treatment compared with the massage control
(p = 0.047). In 2010, Manber et al. [39] conducted a larger
RCT of 150 pregnant women and demonstrated signifi-
cantly decreased symptom severity in the acupuncture
group (p < 0.05) compared with combined control subjects
or sham alone, as well as significantly greater response
rates (63.0 %) compared with combined controls (p < 0.05)
or sham alone (p < 0.05). In 2007, Bosco Guerreiro da Silva
[40] similarly investigated emotional complaints in
pregnancy by quasi-randomising 51 women to a pre-
programmed acupuncture protocol with four optional
points or a non-treatment control. Symptom severity
reportedly reduced by up to 50 % in 15 (60 %) of 25
subjects in the acupuncture group compared with 5
(26 %) of 19 in the control group (p = 0.013). In
addition, significant reductions in the impact of
distress in 3 of 5 life disturbance categories were
also reported (p < 0.05). Whilst the findings of these
three trials appear encouraging, the overall methodo-
logical quality is limited by small sample sizes [38, 40],
quasi-randomisation and lack of an equivalent attention
control [40], unclear randomisation generation and con-
cealment [9, 38], unclear assessor blinding [9, 38, 40], and
incomplete baseline and outcome data [9, 38]. Participant
and practitioner blinding was performed in the two RCTs
[38, 39], as was outcome assessor blinding in one [9, 39].
In all three studies, emotional distress was clinically
evaluated.
How acupuncture may reduce depressive symptomology
remains uncertain; however, one mechanism by which it
may exert an effect is via the oxytocinergic system. This
system, regulated by both oxytocin (OT) hormone levels
and oxytocin receptor (OTR) activity [41], is responsive to
stressors of both physical and psychological origin [42].
The resultant anti-anxiolytic, anti-depressive and stress re-
ducing effects [41, 43] appear to result from adjustments
to the hypothalamic–pituitary axis, autonomic nervous
system activity [44] and reward centres in the brain [43].
A multitude of physical [42], psychosocial, emotional and
behavioural functions [44–48], including mental health
and parental-infant bonding [49], have been attributed to
this system, and, not surprisingly, disruptions within it are
also implicated in a plethora of negative emotional and
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social phenotypic traits [50]. Studies of the relationship
between mental health and the oxytocinergic system are
suggestive of dysregulation [51], as lowered [52–60] and
elevated OTand OTR levels [51, 61–66], as well as dysreg-
ulated patterns of peripheral OT release [66], are seen in
participants with depression in a variety of different obser-
vational and experimental conditions. The influence of
acupuncture upon this system has also been assessed in
12 rodent studies and 1 human study, in which significant
positive regulatory effects were reported, directly via
radioimmunoassay and/or enzyme-immunoassay or quan-
titative real-time polymerase chain reaction (qRT-PCR)
analysis [67–74], as well as indirectly via assessment of
behaviour [75–79]. Further indirect evidence has been
provided by 11 human studies examining acupuncture for
the preparation, induction or enhancement of labour.
Among these studies, significantly reduced requirements
for syntocinin augmentation were reported in the acu-
puncture groups of nine studies [80–88], as was a trend
toward less need in the acupuncture group of another
[89]. In the remaining study, acupuncture was performed
in addition to intravenous syntocinin, and labour effective-
ness rates were also significantly improved [90]. Marginal
non-significant elevations in syntocinin use were reported
in two similar studies [91, 92]; however, methodological is-
sues in both cases may have compromised the results.
As preliminary evidence is suggestive that acupuncture
may be beneficial in reducing the severity of antenatal
depression and may exert a regulatory effect upon the
oxytocinergic system, additional research is warranted to
determine whether acupuncture is a viable alternative
therapeutic option. The aim of this study is to conduct
an RCT to examine the hypotheses that acupuncture,
compared with an attention comparator or usual care,
reduces the severity and duration of antenatal depres-
sion, stress and anxiety; decreases adverse maternal and
infant outcomes; improves maternal quality of life and




A pragmatic, parallel-group RCT will be conducted
to compare individually tailored, semi-standardised,
depression-specific acupuncture with an equivalent
attention progressive muscle relaxation (PMR) compara-
tor and usual care. The morbidity of this population is
sufficiently serious to maintain existing treatment and
evaluate the interventions as adjunctive therapies [93].
The trial design incorporates individualised treatment
flexibility [94], typical of a ‘whole systems’ approach
[95, 96], within the framework of a semi-standardised
protocol [97–100] and is thereby reflective of the re-
cent emphasis on effectiveness studies of acupuncture
interventions to maintain ecological validity [101] as
well as generalisability and interpretability [98, 99].
The non-specific, placebo-like effects resulting from
intervention participation [102, 103] will be estimated
via the attention comparator, whereas antenatal depression
progression or remission and compliance to standard ther-
apy will be monitored via the non-treatment control [100].
Ethical approval for this study was granted in February
2015 by the Research and Ethics Office of the New South
Wales Department of Health, South West Sydney Local
Health District (SWSLHD-HREC/14/LPOOL/400) and
the Western Sydney University Human Research Ethics
Committee (WSU-HREC/H10993). The trial is registered
with the Australian New Zealand Clinical Trials Registry
(ACTRN12615000250538). The protocol (version 1.0) has
been designed in accordance with the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guidelines for interventional trials [104, 105] (see
Additional file 1) and will be conducted in accordance
with the Declaration of Helsinki (1964) and the Inter-
national Conference on Harmonization Good Clinical
Practice (1996). Any changes that need to be made to the
trial protocol will be communicated to all investigators,
the ethics committees and the trial registry.
Eligibility criteria
Women will be eligible if they are at 24 weeks of gestation,
≥18 years of age, have mood disorders and score ≥13 on
the Edinburgh Postnatal Depression Scale (EPDS) [106]
(indicative of a high probability of current depression)
[106, 107]. Women will be excluded if they are experi-
encing a medically diagnosed major depressive episode
≥2 years in duration and/or have psychotic or manic
features rendering them incapable of consent, post-
traumatic stress disorder with needle phobia, a current
psychiatric assessment of suicidal risk, a condition ne-
cessitating bed rest, and/or other major obstetric risks.
Participants must also agree not to receive acupuncture
or PMR other than that provided within the study.
Recruitment, setting and informed consent
The study is being conducted at two hospital sites in South
Western Sydney, Australia. Both sites provide antenatal
outpatient services and are under the governance of the
same health authority; however, birthing services are avail-
able only in the larger of the two. The region serviced in-
cludes suburbs considered to be of disadvantaged SES
[108], high ethnic diversity and greater than state average
indigenous population density [108, 109]. Pregnant women
will be introduced to the study via flyers included in ante-
natal information packs. Antenatal staff will additionally
supply a study poster to all women identified with elevated
EPDS scores during routine antenatal screening. Details of
these women will be provided to the researcher, who, upon
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contact, will forward participant information sheets to all
interested potential recruits. Once agreeing to join the
study, all women will be further screened and, if eligible,
randomised after signed informed consent forms contain-
ing separate provisions for the collection and use of bio-
logical specimens have been obtained in every case
(Additional file 2).
Randomisation and blinding
Participants and practitioners are not blinded to the study;
however, data entry and analysis will be blinded. The ran-
domisation schedule was computer-generated to contain
three groups of random numbers, enabling stratification for
the three different models of antenatal care (obstetrician,
standard and caseload midwifery) as well as to randomly
contain ‘blocks of three’ within each group, acupuncture,
PMR or usual antenatal hospital care (1:1:1). The schedule
was generated by the school statistician (Paul Fahey) and
concealed in opaque envelopes by an independent re-
searcher from the National Institute of Complementary
Medicine (NICM) (Anthony Good).
Treatment and assessment schedules
The study period will run for 8 consecutive weeks from
gestation week 24 to the end of week 31 (Fig. 1). At
baseline, age, gestational age, number of previous preg-
nancies and/or births, relationship status and/or quality,
education, employment status and country of birth will
be collected, along with depression-related clinical data,
including medical diagnoses, entry EPDS score, age of
onset and length of index episode, number and severity
of past depressive episodes, length and severity of
current episode, family history of depression and current
medication and/or psychotherapy use. Collected data
will be de-identified and securely stored at the NICM.
Safety monitoring
Owing to the morbidity of this population, women will
undergo a weekly psychological assessment with the
Kessler 6 (K6) instrument [110], either during the weekly
session (intervention groups) or by telephone (usual
care). If notable worsening or a ‘cut-off ’ score is reached,
immediate referral will be made to hospital antenatal
mental health services. Any adverse events arising from
the acupuncture intervention will be documented and
reported to Western Sydney University and the South West
Sydney Local Health District, and prevalence will be calcu-
lated. Such events are reportedly rare (occurring approxi-
mately 1.3 times every 1000 treatments) and generally of a
mild [111, 112] to moderate nature [112]. However, if such
EPDS ≤ 13 EPDS ≥ 13
Gestation (G) age < 24 weeks - EPDS screening of all women 
Informed Written Consent, Recruitment and Baseline Data Collection
Model of Care Stratification & Computer Generated Randomisation 
Ineligible
G24 – Pre Intervention Saliva, Blood, EPDS, DASS - 21 and WHOQoL - 26 Questionnaire Data Collected 
Hospital Care & PMRHospital Care Hospital Care & Acupuncture 
G24 – G27: K6 & Acupuncture G24 – G27: K6 & PMR G24 – G27: K6 Weekly  
6 Week Post-Partum – EPDS, DASS - 21, WHOQoL - 26 and BaM – 13 Questionnaire Data Collected
G31 – End of Intervention Saliva, Blood, Sleep, EPDS, DASS - 21 and WHOQoL - 26 Questionnaire Data Collected 
G28 – G31: K6 & PMR 
G 27 – Saliva, EPDS, DASS - 21, and WHOQoL - 26 Questionnaires & Sleep Data Collected 
G 31 Intervention Questions Data Collected
G 27 Intervention Questions Data Collected
G28 – G31: K6 Weekly  G28 – G31: K6 & Acupuncture 
Fig. 1 Pragmatic randomised controlled trial treatment flowchart. EPDS Edinburgh Postnatal Depression Scale, G gestational week, DASS-21
21-item Depression Anxiety and Stress Scale, WHO-QoL-26 26-item World Health Organisation Quality of Life Scale, K6 Kessler 6 instrument,
PMR progressive muscle relaxation, BaM-13 13-item Being a Mother Scale
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events do occur, participants will be reminded of their right
to withdraw from the study at any time.
Interventions
In the first session, a full case history will be taken and a
traditional Chinese medicine (TCM) and meridian ther-
apy diagnosis will be made. This will also occur for the
usual care group upon trial entry. The intervention
groups will then receive weekly 1-h treatments over the
8-week period. At the end of each session, 5 minutes will
be spent gaining feedback regarding the session. Treat-
ments will be conducted in the antenatal clinics of either
hospital or at the NICM.
The acupuncture protocol draws upon TCM theoretical
foundations and treatment strategies as well as some gener-
alisable traditional East Asian medicine approaches. The
three-stage semi-standardised flexible process (Fig. 2) incor-
porates a ‘root’- and ‘branch’-style treatment [113, 114] as
well as auricular acupuncture. The ‘root’ treatment (step 1)
aims to provide a fundamental harmonisation via the extra-
ordinary meridian system, while the ‘branch’ treatment
(step 2) focuses on remaining disruptions in a more symp-
tomatic way [114–116]. Use of the extraordinary meridian
system as a root-style approach has been suggested to facili-
tate a longer-lasting, more penetrating effect [114, 116] by
virtue of this system’s ability to regulate the ‘qi’ of all of the
yin-and-yang channels [117], access and distribute ‘pre-
heaven essence’ throughout the entire body [116, 118] and
affect a person at a constitutional level, due to its embryo-
logical roots [116, 118, 119]. Specific functions relevant to
depression include influences to the marrow [116], brain,
spinal chord, hypothalamic–pituitary–ovarian axis [120],
circulatory, hepatic, biliary [121] and endocrine [118] sys-
tems. Pathology within this system is thought to manifest
in the mind or ‘shen’ [118], and as such treatment is recom-
mended for mental and/or emotional problems [118, 120]
as well as cases of mixed pattern complexity involving
multiple meridians [118]. In step 1, diagnosis of the most
disharmonious extraordinary meridian pair will be made on
the basis of the presence of relevant mood disturbance
symptomology [116] in combination with disease indicating
palpatory findings along involved channel trajectories
[117–119]. If uncertainty remains regarding which of the 2
points of the meridian pair will be the master point (MP),
each point will be tested with acupressure to see which one
provides the greatest meridian improvement. After identifi-
cation, the gender-appropriate MP and coupled point (CP)
(Table 1) will be unilaterally needled with the meridian flow
to ensure that the areas traversed by both vessels are influ-
enced [118]. This method was recommended by Maciocia
in 2006 [118] for problems of the head and internal organs,
weakened body condition and anxiety. It is also suitable for
pregnant women in side-lying position. Japanese-style prac-
titioners typically apply polarity devices to the MP and CP
to remedy detected pathologies in the extraordinary vessel
system [119, 122]. However, for the purposes of generalis-
ability, polarity in this case will be achieved by side of sex-
directed unilateral needling and reverse-order withdrawal
[116]. Whilst needles are retained for 10–15 minutes,
further diagnosis will be performed by palpation and ques-
tioning. As many of the symptoms of depression corres-
pond to TCM ‘yang deficiency’ such as lethargy, reduced
libido and lack of motivation [116], it has been theorised
that disruption to the major yang channel, the extraordin-
ary meridian governor vessel (GV) that traverses the middle
of the back and head, is implicated in depression [123].
Treatment recommended by Wang and Zhang in 2010
[123] is the needling of the most painful or obstructed
points along this channel or on the slightly adjacent Huato
Jia Ji (HJJ) points, serving a dual main channel and extraor-
dinary vessel function [118]. Step 2a will involve needling of
the two points located in this way, in combination with ei-
ther GV 20 (bai hui) [124] +GV 16 (feng fu) [124], the ‘Sea
of Marrow’, indicated for mania, suicidal tendencies and
calming the spirit; or ‘Shi Shen Cong 4-4 Alert spirits’, indi-
cated for mania, depression, insomnia and calming of the
spirit [117]. Selection in either case will be based upon pal-
pation tenderness and/or symptom differentiation. Whilst
these needles are retained, step 2b will involve the needling
of two to six additional tender points, if required, according
to numerous theoretical possibilities (see Tables 2 and 3)
Step 1
Palpate GV Line & HJJ  Select 2 most painful
Step 2a
Whilst retained add
GV 16 & GV 20 or Shi Shen Cong 4
+ Step 2 b:
After a total of 15 - 20min remove needles
Step 3
‘Root’ – Needle MP RHS, CP LHS of disharmonious 
Extraordinary Meridian Pair – 10 -15 min. 
Remove in the reverse order. Needle 2 most painful 
GV line or HJJ points – retain for 15 min.
Add up to 2-6 points – based on presenting  
symptoms - see table 2 - 3 for options 
Add 2 press balls to auricular points for retention – 
see table 4 for options
Fig. 2 Acupuncture treatment flowchart. CP coupled points, GV
governor vessel, HJJ Huato Jia Ji, LHS left-hand side, MP master points,
RHS right-hand side
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such as the ability to clear reflex areas, for a combined total
time of 15–20 minutes. A step 2b example is the associ-
ation between depression and inflammation [125] viewed
as ‘heat’ in TCM; hence, if detected at a ‘fire’ point on a me-
ridian trajectory, a remedying treatment involving the need-
ling of ‘water’ and ‘metal’ points’ [116] to extinguish the
‘fire’, may be selected. Step 3 will then comprise two stain-
less steel pellets (Helio Supply Co., San Jose, CA, USA)
being placed on appropriate points in the ear (Table 4) to
extend the treatment effect [122] for an additional 5 days.
Lifestyle and dietary advice, contraindicated labour aug-
mentation points [126] and painful needling techniques will
be avoided [127]. Needles will be inserted into the most
sensitive area within the specified point location or ‘live’
point [100] to a depth enabling retention (2–6 mm), either
perpendicularly (even technique) or obliquely with the
Table 1 Master and coupled point pairings of the eight extra vessels
Extraordinary meridian Master point (right) Couple point (left)
Ren Mai – Directing Vessel Lung (LU) 7 (lie que)a Kidney (KD) 6
Yin Qiao Mai –Yin Heel Vessel Kidney (KD) 6 (zhao hai) Lung (LU) 7
Chong Mai – Penetrating Vessel Spleen (SP) 4 (gong sun) Pericardium (PC) 6
Yin Wei Mai – Yin Linking Vessel Pericardium (PC) 6 (nei guan) Spleen (SP) 4
Dai Mai – Girdle Vessel Gallbladder (GB) 41(zu lin qi) Triple burner (TB) 5
Yang Wei Mai – Yang Linking Vessel Triple burner (TB) 5 (wai guan) Gallbladder (GB) 41
Du Mai – Governing Vessel Small intestine (SI) 3 (hou xi) Bladder (BL) 62
Yang Qiao Mai – Yang Heel Vessel Bladder (BL) 62 (shen mai) Small intestine (SI) 3
The eight extra vessels are described by Maciocia [116].
aFrom Ellis et al. [124]
Table 2 Step 3: Additional relevant point possibilities
Symptom and theoretical foundation Points
Severe Yang deficiencya GV 4 (ming men)b and GV 14 (da zhui) or GV 4 and TB 4
(yang chi)
Anxiety + pressure pain at PC 8 (lao gong) or SP 2 (da du) – pericardium
or spleen metal and water pointsc,d
PC 3 (qu ze) and 5 (jian shu) or SP 5 (shang qiu) and 9
(yin ling quan)
Anxiety + pressure pain at CV 12 (zhong wan) – points of the heart shu aread T5/HJJ/BL 15 (xin shu)/BL 44 (shen tang)/BL 49 (yi she)
Anxiety + pressure pain at CV 17 (dan zhong)d GB 13 (ben shen)
Depression/mental disturbance – ‘blood stagnation in the head’c First – SP 9 (yu ling quan) second – PC 8 or PC 6 or PC 3 + 5
Depression due to adrenal exhaustionc,d KD 6 and lateral to LU 5 (chi ze) or KD 6 and KD 27 (shu fu)
Depression and sphenoid bone disturbance – pressure pain at GB 4 (han yan)/5
(xuan lu)/6 (xuan li)d
Needle most tender
Depression and sphenoid bone disturbance – pressure pain TB 17 (yi feng) and TMJc KD 9 (zhu bin) and 27 and above TB 9 (si du) side of pain
Depression and pituitary disturbancec SI 3, SI 13 (qu yuan), BL 2 (zan zhu) and 1 cun above BL 10
(tian zhu)
Melancholic depressiond – if positive for pressure pain/pulsation at CV 9 (shui fen)d ST 24 (hua rou men) RHS, LU 9 (tai yuan)
Depression – LR 2 (xing jian) pressure pain – water and metal pointsc LR 4 (zhong feng) and 8 (qu quan)
Depression – pressure pain LR organ region and LR 14 (qi men)c LHS – lateral to LU 5 (chi ze), LR 4 and LR 14 RHS
Chronic depression and weakened immune system – pressure pain R ST 26
(wai ling)/27 (da ju ) and TB 16 (tian you)c
Tender point around LI 10 (shou san li)/11 (qu chi)
Subclinical underactive thyroid glandc Eustachian, TB 4, KD 9/10 (yin gu), BL 43 (gao huang shu),
HJJ C6/7
Inflammation – TCM meridian heat signs – metal and water points to extinguishe Meridian-dependent
Mental health relevant points – selected by point function and palpation tenderness See Table 3 for options
BL bladder meridian, CV conception vessel, GB gallbladder meridian, GV governor vessel, HJJ Huato Jia Ji, KD kidney meridian, LHS left-hand side, LU lung meridian,
LI large intestine meridian, LR liver meridian, PC pericardium meridian, SP spleen meridian, ST stomach meridian, RHS right-hand side, SI small intestine meridian,
TB triple burner meridian, TCM traditional Chinese medicine
aMaciocia [116]
bEllis et al. [124]
cMatsumoto and Euler [134]
dMatsumoto and Euler [135]
eKendall-Tackett [125]
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Table 3 Possible points and point combinations useful for the treatment of antenatal depression
Points Indications/Symptom alleviation
ST 40 (feng long)a Spleen deficiency, damp and phlegm misting – heaviness, confusion, metal disturbance
ST 23 (tai yi) Transforms phlegm and calms the spirit – mania, depression, agitation
ST 24 (hua rou men) Transforms phlegm and calms the spirit – mania, depression
LR 3 (tai chong) LR Qi stagnation, irritability, feeling of oppression
BL 42(po hu) Breathing difficulties, grief, worry, sadness
BL 43 Increases spleen yang and lung function, calms the spirit, resolves phlegm
BL 44 Calming and mental clarity
BL 47 (hun men) Enables clear and positive life planning and decision making
BL 47 and BL 52(zhi shi) Together adds stability to plans and decisions, also for LR Qi stasis attack on lungs
BL 49 Obsessive thinking, improved memory and concentration
BL 52 Willpower, determination, initiation
BL 52 and BL 42 Willpower and emotional release
BL 52 and BL 44 Willpower, calming, anxiety, depression, mental restlessness and insomnia
BL 52 and BL 47 Willpower and life direction, chronic depression with mental exhaustion, apathy and despondency
BL 52 and BL 49 Willpower, obsessive thoughts, worry and confusion
BL 10 (tian zhu) Calms the spirit
BL 17 (ge shu) Mania, depression
GV 18 (qiang jian) Liver blood deficiency, calming, mental restlessness, agitation, confusion, obsessive thinking
GV 19(hou ding) Willpower, calming, anxiety, mental restlessness, kidney yin deficiency heat
GV 19 and CV 15 (jiu wei) Calming, insomnia, mental restlessness
GV 20 (bai hui) Lifts mood, aids memory and concentration
GV 21(qian ding) Anxiety, insomnia, depression
GV 24 (shen ting) Clears the mind
GV 24 and GB 13 Calming, anxiety, mental restlessness due to LR causes
CV 14 (ju que) Transforms phlegm and calms the spirit
CV 15 Calming, chest oppression
GB 9 (tian chong) Calms the spirit and pacifies fright
GB 12(wang gu) Mania, agitation of the heart and insomnia
GB 13 Calming, mental clarity, severe anxiety and mental restlessness resulting from LR disharmony
GB 13 and GV 24 Same as for GB 13 with enhanced calming effect
GB 13 and HT 7 (shen men) Calming, severe anxiety due to heart disharmony
GB 15 (tou lin qi) Calms the spirit, reduces emotional fluctuations and obsessive thinking
GB 17 (zheng ying) Calms the spirit, aids memory and concentration
GB 18 (cheng ling) Stops obsessive thoughts, strengthens the function of the lungs and clears the nose
GB 40 (qiu xu) Willpower, difficulty making decisions
HT 7 Calms the spirit, heart blood and yin deficiency
HT 6 (tong li) Calms the spirit, repletion patterns with vacuity heat
HT 8 (shao fu) Calms the spirit – agitation, fright palpitations, depleted sadness and worry
HT 9 (shao chong) Calms the spirit – mania, depression, severe mental restlessness, anxiety, insomnia
HT 5 (tong li) Calms the spirit – depressive disorder
PC 4 (xi men) Calms the spirit – agitation, insomnia, melancholy, spirit qi deficiency
HT 7 and PC 6 Calms the spirit – shen disturbance, anxiety, mental restlessness
KD 7 ( fu liu) and HT 6 (yin xi) Calms the spirit – heart and kidney not communicating, agitation, insomnia, anxiety
PC 5 Settles and calms the spirit – mania and agitation
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meridian flow (tonification) and taped in place to allow for
adjustment of position during the session. AcuGlide (Helio
Supply Co.) single-use stainless steel needles 0.16 mm×
30 mm will be used predominantly, with 0.14-mm or
0.12-mm needles selected for tenderer locations.
In our examination of recent reviews of acupuncture as a
treatment for depression [35, 36, 128–130], we identified
three main treatment approaches previously used: (1) fixed
points for mood disturbance alleviation, (2) fixed points of
this function in combination with additional points selected
Table 3 Possible points and point combinations useful for the treatment of antenatal depression (Continued)
PC 7 (da ling) Calms the spirit – depressive disorder
PC 6 Calms the spirit, lifts mood – qi stagnation emotional problems, anger, resentment and frustration
PC 6 and SP 4 Opens yin wei mai, nourishes blood, relaxes the chest, calms the spirit
PC 6 and LR 3 Resolves qi stasis from repressed anger
PC 6 and GV 20 Lifts the mood, relieves depression
PC 6 and GV 26 (shu gou) Lifts the mood, opens heart orifices, relieves depression
SI 7 (zhi zheng) Calms the spirit – mania, depression, anxiety, sadness, fear and fright
KD 9 (zhu bin) Clears the heart and transforms phlegm – mental restlessness, mania, depressive disorders
SI 7 and HT 3 (shao hai) Chronic anxiety, depression, fear or emotional distress
LI 5 (yang xi) Calms the spirit – mania, depression
BL bladder meridian, CV conception vessel, GB gallbladder meridian, GV governor vessel, HJJ Huato Jia Ji, KD kidney meridian, LHS left-hand side, LU lung meridian,
LI large intestine meridian, LR liver meridian, PC pericardium meridian, SP spleen meridian, ST stomach meridian, RHS right-hand side, SI small intestine meridian
Information is from MacPherson and Schroer [98]; Schnyer and Allen [99]; Deadman et al. [117]; Matsumoto and Euler [136]; and Rogers and Rogers [147]
aEllis et al. [124]
Table 4 Auricular point possibilities
Name Function
Point Zero Homeostasis, will power
Shen men Pain, tension, anxiety and depression
Sympathetic tone Sympathetic nervous system balance
Cheerfulness Relieves depression
Excitement Relieves hypersomnia and depression
Master cerebral point Anxiety, worry, obsessive compulsive disorders, psychosomatic disorders and chronic pain
Master oscillation point Balances left and right cerebral hemispheres
Sleep disorders 1 Relieves insomnia, nervousness





Thyroid 1–4 Thyroid function disturbance
Marvellous/wonderful Lifts mood
Aggression Alleviates aggression/irritability
Mania Relieves manic symptomology
Insomnia For sleep disturbance
Vitality For lethargy and despondency
Stress control Relieves stress
Tranquilizer Calms the spirit
Guilt Alleviates feeling of guilt
Overwhelmed Stress, emotional paralysis, despondency
Burdened Emotional paralysis, despondency, overwhelm
Adapted from several different Chinese medicine–based auricular maps obtained from the internet: https://www.google.com.au/search?q=chinese+auricular+ear
+acupuncture+chart&biw=1140&bih=610&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjO6ofuuebKAhXEUZQKHR-UAAkQsAQIGg.
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according to TCM pattern differentiation and (3) flexible
point selection based entirely upon TCM pattern discrimin-
ation. Variations included diagnosis of disrupted extraor-
dinary vessels Chong and Ren in one study [131], an
abdominal points focus in another [132] and scalp acu-
puncture in a third [133]. Many studies included auricular
acupuncture as well as multiple points along the extraor-
dinary GV meridian. Two research groups developed flex-
ible manualised protocols based on pattern differentiation
[98, 99], one of which also provided modifications for preg-
nancy [99]. Both have been drawn upon for therapeutic
possibilities presented in Tables 2 and 3, in combination
with those suggested by Matsumoto and Euler in 2002
[134] and 2008 [135], such as for the alleviation of com-
monly observed LR Qi stagnation [98]. It is theorised that
the approach of extraordinary meridian treatment in com-
bination with mental disturbance–oriented pattern differ-
entiation and symptom alleviation may provide additional
therapeutic outcomes. In 2009, Finston [136] used a similar
strategy in patients with severe mental disorders and re-
ported significant reduction or alleviation of psychotic
symptoms [136].
The PMR comparator has been adapted from previous
research [137] to achieve overall body relaxation in all ses-
sions with an additional weekly focus as follows: introduc-
tion (week 1); lower legs and knees (week 2); upper legs
and buttocks (week 3); lower back and pelvic floor (week
4); upper back and chest (week 5); arms and shoulders
(week 6); head, face and neck (week 7); and integration
(week 8). Participants, whilst lying in a comfortable pos-
ition, will be guided through the PMR in a one-to-one for-
mat. A participant who is unable to attend will be offered
either a recording- or telephone-based session for home
administration.
All groups will continue standard antenatal care,
which may include medication and or counselling as
well as antenatal classes. In compensation for not receiv-
ing treatment, the usual care group will be offered four
acupuncture sessions after collection of final data at
6 weeks post-natally.
The principal investigator of this trial (SMO) has 14 years
of full-time clinical experience and will conduct all acu-
puncture sessions, unless unable, in which case a backup
acupuncturist with 14 years of part-time clinical experience
will be employed. Both practitioners have bachelor’s degrees
in acupuncture and are registered with the Chinese Medi-
cine Board of Australia and the Australian Acupuncture
and Chinese Medicine Association. The principal investiga-
tor will also conduct all PMR sessions, unless unable, in
which case a backup associate researcher will be employed.
Outcome measures
Data and samples will be collected at various time points,
including baseline, mid-intervention (week 4), end of
intervention (week 8), birthing and hospital discharge
(medical records) and 6 weeks post-natally. All question-
naires will be self-administered and collected by the princi-
pal investigator. The primary outcome endpoint, reduction
in depression severity, will be assessed at baseline, at 4 and
8 weeks from trial entry and at 6 weeks post-natally via the
EPDS, an extensively validated, clinically sensitive [138], 10-
item self-report questionnaire. Additional secondary out-
come endpoints will also be examined as follows :
1. At the same time points as the EPDS, reduction in
stress and anxiety will be monitored with the 21-
item Depression Anxiety and Stress Scale (DASS-21)
[139] and improvement to quality of life will be eval-
uated using the 26-item World Health Organisation
Quality of Life Scale (WHO-QoL-26,) [140]. The
DASS-21 is a short form of the clinically validated
[141] and cross-culturally reliable [142] self-report
measure of emotional states of stress and anxiety.
The WHO-QoL-26 [140] is also an abbreviated form
of this discriminant, content valid, internally consist-
ent and reliable self-report measure for overall qual-
ity of life.
2. Adjustment to parenting and maternal-infant bond-
ing will be evaluated at 6 weeks post-natally via the
13-item Being a Mother Scale (BaM-13) [143]. The
BaM-13 is a clinically discriminating, reliable and
valid self-report tool specifically designed to enable
early assessment of women’s experiences of
motherhood.
3. Maternal-infant outcomes such as gestational diabetes,
mode of delivery, method of pain relief, labour
augmentation, post-partum haemorrhage, breastfeeding
level and duration, gestational age at delivery, birth
weight, 1- and 5-minute Apgar scores, neonatal inten-
sive care unit admission and need and reason for resus-
citation and or intensive care will be assessed at
delivery, discharge and 6 weeks post-natally.
4. Salivary OT levels will be determined using saliva
specimens collected by the principal investigator at
baseline and at 4 and 8 weeks from trial entry.
Leucocyte OTR messenger RNA (mRNA) expression
will be assessed using blood collected by phlebotomists
at local pathology centres at baseline and 8 weeks from
trial entry.
Every effort will be made to minimise missing data by
ensuring weekly contact with participants during the
intervention period as well as robust follow-up at later
data collection points. Missing data for the primary
endpoint of depression will be estimated using multiple
imputation data derived from the K6 instrument. All
missing data will be reported with reasons given and
patterns of occurrence explored.
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Sample analysis
The principal investigator will process samples as fol-
lows. 4 ml of saliva will be obtained via passive drool
into sterile CELLSTAR polypropylene test tubes (15 ml,
catalogue number 188271; Greiner Bio-One, Frickenhau-
sen, Germany), transported on ice and frozen and stored
at −20 °C. Thawed samples will later be batch-processed
and concentrated using equilibrated Sep-Pak C18 200-
mg resin cartridges (catalogue number WAT 054945;
Waters Corporation, Milford, MA, USA) before refreez-
ing at −20 °C in 5-ml sterile Eppendorf tubes (catalogue
number 0030119401, Eppendorf, Hauppauge, NY, USA).
Triplicate OT concentrations will be batch-calculated
using an OT enzyme-linked immunosorbent assay
(ELISA) kit (catalogue number ADI-901-153A-0001;
Enzo Life Sciences, Farmingdale, NY, USA) and an
ELISA plate reader. Blood (2.5 ml) collected into PAX-
gene blood tubes (catalogue number 762165; BD Diag-
nostics, Hunt Valley, MD, USA) will be stored at −20 °C
no sooner than 2 h after collection. Batch extraction of
mRNA will later be performed using PAXgene blood
RNA kits (catalogue number 762174; BD Diagnostics)
and stored at −20 °C before cDNA libraries are made
using iScript Advanced cDNA Synthesis kits (170-8843
Bio-Rad Laboratories, Hercules, CA, USA) and mRNA
expression is determined by qRT-PCR using human
OTR PCR primers (catalogue number VHPS-6555; Ap-
plied Biosystems, Foster City, CA, USA).
Sample size
Mean antenatal EPDS scores extracted from a recent
Australian study [111], as well as estimated post-
intervention between-groups differences derived from a
meta-analysis of two antenatal depression acupuncture
studies [9], were used for a power calculation for this
study. Using a power of 80 % and two-sided testing at a
5 % significance level, detecting a significant difference
in end of intervention mean ± standard deviation (SD)
EPDS scores of 8.9 ± 5 for the acupuncture group plus
usual hospital care versus 13 ± 6.5 for usual hospital care
will require a total recruitment goal of 75 participants.
As high attrition rates have been reported for this popu-
lation [144], an additional recruitment of 30 % has been
added, resulting in a total goal of 96, or 32 participants
per group.
Statistical analysis
Descriptive statistics will be used to describe the charac-
teristics of the study population. An intention-to-treat
analysis will be undertaken [145], with between-groups
differences explored using analysis of variance for the
primary and secondary endpoints of depression, stress,
anxiety, quality of life and OT/OTR. Effect sizes will be
reported with 95 % confidence intervals, and results will
be considered significant if p values are less than 0.05.
Discussion
In consideration of the sufficiently serious consequences of
antenatal depression in combination with therapeutic defi-
ciencies, a thorough evaluation of any promising preventa-
tive and or therapeutic techniques that may be effective in
reducing antenatal distress is required. As to date no studies
have been conducted to investigate an acupuncture protocol
of this type in depressed pregnant women or to evaluate the
effects of acupuncture on the oxytocinergic system in this
regard, it is the aim of this RCT to collect such data as well
as to assess the usefulness of this acupuncture treatment for
the alleviation of antenatal depression. Limitations of this
study include the current lack of research evidence regard-
ing the effectiveness of the proposed acupuncture treat-
ment strategy, the use of self-report measures for the
determination of treatment effect, a ‘practice effect’ that
may occur due to repeated use of self-report measures
and the unquantifiable possible effects of PMR that
are in addition to non-specific placebo effects result-
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